RxDoctor Payments Data

Melinda Cherrington

Family · Kansas City, MONPI 1801156633

Payments from drug & device makers

$3,461in general payments, 2019–2025

Across 186 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$730
  • Coloplast$656
  • Astellas Pharma US Inc$569
  • Convatec Inc.$328
  • Endo USA, Inc.$138
  • Rochester Medical Corporation$131
  • plus $909 from 14 others

What the payments were for

  • Food & beverage$3,00387%
  • Education$45813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic16$730
Coloplast92$656
Astellas Pharma US Inc10$569
Convatec Inc.16$328
Endo USA, Inc.6$138
Rochester Medical Corporation5$131
180 Medical, Inc.6$117
C. R. Bard, Inc. & Subsidiaries4$116
Endo Pharmaceuticals Inc.5$105
ABC Home Medical Supply, Inc.5$92
Urogen Pharma, Inc.3$86
Merck4$86
Hollister Incorporated3$61
Ferring Pharmaceuticals Inc.2$60
KARL Storz Endoscopy-america2$53
Vertex2$45
Pfizer2$38
Tolmar, Inc.1$19
AbbVie1$15
Boston Scientific1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,461 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$30,216
Medicare patients
203
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron127$103,865
ElmironPentosan Polysulfate Sodium17$17,869
Trospium Chloride171$10,240
Solifenacin Succinate164$7,152
Mirabegron ErMirabegron11$6,666
Tamsulosin Hcl435$6,068
Methenamine Hippurate61$4,890
Finasteride375$4,464
Tolterodine Tartrate ErTolterodine Tartrate41$4,286
Potassium Citrate ErPotassium Citrate21$3,175
Alfuzosin Hcl ErAlfuzosin Hcl95$2,363
Cefpodoxime Proxetil20$2,309
Desmopressin Acetate44$2,193
Estradiol18$1,103
Oxybutynin Chloride58$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$569$103,865127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.

Other family in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →